{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:37:40Z","timestamp":1794641860900,"version":"4.9.1"},"reference-count":89,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,4,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>As the risks of allogeneic blood transfusion (ABT)\u2013transmitted viruses were reduced to exceedingly low levels in the US, transfusion-related acute lung injury (TRALI), hemolytic transfusion reactions (HTRs), and transfusion-associated sepsis (TAS) emerged as the leading causes of ABT-related deaths. Since 2004, preventive measures for TRALI and TAS have been implemented, but their implementation remains incomplete. Infectious causes of ABT-related deaths currently account for less than 15% of all transfusion-related mortality, but the possibility remains that a new transfusion-transmitted agent causing a fatal infectious disease may emerge in the future. Aside from these established complications of ABT, randomized controlled trials comparing recipients of non\u2013white blood cell (WBC)\u2013reduced versus WBC-reduced blood components in cardiac surgery have documented increased mortality in association with the use of non-WBC\u2013reduced ABT. ABT-related mortality can thus be further reduced by universally applying the policies of avoiding prospective donors alloimmunized to WBC antigens from donating plasma products, adopting strategies to prevent HTRs, WBC-reducing components transfused to patients undergoing cardiac surgery, reducing exposure to allogeneic donors through conservative transfusion guidelines and avoidance of product pooling, and implementing pathogen-reduction technologies to address the residual risk of TAS as well as the potential risk of the next transfusion-transmitted agent to emerge in the foreseeable future.<\/jats:p>","DOI":"10.1182\/blood-2008-10-167643","type":"journal-article","created":{"date-parts":[[2009,2,2]],"date-time":"2009-02-02T21:36:13Z","timestamp":1233610573000},"page":"3406-3417","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":512,"title":["Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention"],"prefix":"10.1182","volume":"113","author":[{"given":"Eleftherios C.","family":"Vamvakas","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morris A.","family":"Blajchman","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON; and"},{"name":"Canadian Blood Services, Hamilton, ON"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111715260241900_B1","unstructured":"FDA\/CBER\n          Fatalities reported to FDA following blood collection and transfusion. Annual summary for fiscal year 2007.\n          Accessed November 21, 2008\n          \n            http:\/\/www.fda.gov\/cber\/blood\/fatal07.htm"},{"key":"2019111715260241900_B2","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1046\/j.1537-2995.2002.00202.x","article-title":"Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994 to 1998.","volume":"42","author":"Andreu","year":"2002","journal-title":"Transfusion"},{"key":"2019111715260241900_B3","first-page":"237","article-title":"Serious hazards of transfusion: a decade of hemovigilance in the UK.","volume":"20","author":"on behalf of the SHOT Seeing Group","year":"2006","journal-title":"Trans Med Rev"},{"key":"2019111715260241900_B4","unstructured":"Serious hazards of transfusion (SHOT) Annual Reports.\n          Accessed September 10, 2008\n          \n            http:\/\/www.shot-uk.org"},{"key":"2019111715260241900_B5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.transci.2004.07.005","article-title":"The Quebec hemovigilance system: description and results from the first two years.","volume":"31","author":"Robillard","year":"2004","journal-title":"Transfus Apher Sci"},{"key":"2019111715260241900_B6","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1046\/j.1537-2995.1990.30790385515.x","article-title":"Reports of 355 transfusion-associated deaths: 1976 through 1985.","volume":"30","author":"Sazama","year":"1990","journal-title":"Transfusion"},{"key":"2019111715260241900_B7","first-page":"99","article-title":"Germs, gels, and genomes: a personal recollection of 30 years in blood-safety testing.","volume-title":"Blood Safety in the New Millennium","author":"Dodd","year":"2001"},{"key":"2019111715260241900_B8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.tmrv.2008.01.001","article-title":"Pathogen reduction: A precautionary-principle paradigm.","volume":"22","author":"Alter","year":"2008","journal-title":"Transfus Med Rev"},{"key":"2019111715260241900_B9","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1056\/NEJMoa030969","article-title":"Transmission of West Nile virus through blood transfusion in the United States in 2002.","volume":"349","author":"for the West Nile Virus Transmission Investigation Team","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111715260241900_B10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.tmrv.2007.09.003","article-title":"Transfusion transmission of prion diseases.","volume":"22","author":"Zou","year":"2008","journal-title":"Transfus Med Rev"},{"key":"2019111715260241900_B11","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(07)61779-6","article-title":"Infection with Chickungunya virus in Italy: an outbreak in a temperate region.","volume":"370","author":"for the CHIKV Study Group","year":"2007","journal-title":"Lancet"},{"key":"2019111715260241900_B12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1053\/tmrv.2003.50007","article-title":"The application of the precautionary principle to the blood system: the Canadian blood system's vCJD donor deferral policy.","volume":"17","author":"Wilson","year":"2003","journal-title":"Transfus Med Rev"},{"key":"2019111715260241900_B13","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1161\/01.CIR.97.6.562","article-title":"Beneficial effect of leukocyte depletion of transfused blood on post-operative complications in patients undergoing cardiac surgery: a randomized clinical trial.","volume":"97","author":"van de Watering","year":"1998","journal-title":"Circulation"},{"key":"2019111715260241900_B14","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1161\/01.CIR.0000130162.11925.21","article-title":"Double-blind, randomized controlled trial on the effect of leukocyte-depleted erythrocyte transfusions in cardiac-valve surgery.","volume":"109","author":"Bilgin","year":"2004","journal-title":"Circulation"},{"key":"2019111715260241900_B15","doi-asserted-by":"crossref","first-page":"112a","DOI":"10.1182\/blood.V104.11.380.380","article-title":"Pre-storage leukoreduction of red cells in elective cardiac surgery: results of a double-blind randomized controlled trial.","volume":"104","author":"Boshkov","year":"2004","journal-title":"Blood"},{"key":"2019111715260241900_B16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1751-2824.2008.00168.x","article-title":"Biovigilance initiatives.","volume":"3","author":"Strong","year":"2008","journal-title":"ISBT Science Series"},{"key":"2019111715260241900_B17","first-page":"851A","article-title":"The declining risk of ABO incompatibilities: twelve years of hemovigilance in France.","volume":"118","author":"Renaudier","year":"2007","journal-title":"Blood"},{"key":"2019111715260241900_B18","article-title":"The 2007 Nationwide Blood Collection and Utilization Survey Report.","author":"Whitaker","year":"2008"},{"key":"2019111715260241900_B19","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/tmrv.2003.50009","article-title":"Risks associated with transfusion of cellular blood components in Canada.","volume":"17","author":"Kleinman","year":"2003","journal-title":"Transfus Med Rev"},{"key":"2019111715260241900_B20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1086\/595010","article-title":"Babesia infection through blood transfusions: reports received by the US Food and Drug Administration, 1997-2007.","volume":"48","author":"Gubernot","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2019111715260241900_B21","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1111\/j.0041-1132.2004.04347.x","article-title":"Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel.","volume":"44","author":"Kleinman","year":"2004","journal-title":"Transfusion"},{"key":"2019111715260241900_B22","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/01.moh.0000177829.85904.39","article-title":"Transfusion-related acute lung injury.","volume":"12","author":"Webert","year":"2005","journal-title":"Curr Opin Hematol"},{"key":"2019111715260241900_B23","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1046\/j.1537-2995.1985.25686071434.x","article-title":"Diagnostic and pathogenetic considerations in transfusion-related acute lung injury.","volume":"25","author":"Popovsky","year":"1985","journal-title":"Transfusion"},{"key":"2019111715260241900_B24","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1537-2995.2007.01102.x","article-title":"Transfusion-related acute lung injury surveillance (2003-2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross.","volume":"47","author":"Eder","year":"2007","journal-title":"Transfusion"},{"key":"2019111715260241900_B25","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1046\/j.1537-2995.2003.00466.x","article-title":"Single hospital experience of TRALI.","volume":"43","author":"Wallis","year":"2003","journal-title":"Transfusion"},{"key":"2019111715260241900_B26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1046\/j.1537-2995.1999.39199116901.x","article-title":"Prevalence of HLA sensitization in female apheresis donors.","volume":"39","author":"Densmore","year":"1999","journal-title":"Transfusion"},{"key":"2019111715260241900_B27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1537-2995.2001.41030317.x","article-title":"A randomized controlled trial of transfusion-related acute lung injury: is plasma from multiparous blood donors dangerous?","volume":"41","author":"Palfi","year":"2001","journal-title":"Transfusion"},{"key":"2019111715260241900_B28","unstructured":"Strong\n              DM\n            \n            \n              Shoos Lipton\n              K\n            \n          \n          Transfusion-related acute lung injury. AABB Association Bulletin #06-07 (November 3, 2006).\n          Accessed November 14, 2008\n          \n            http:\/\/www.aabb.org\/Content\/Members_Area\/Association_Bulletins\/"},{"key":"2019111715260241900_B29","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1182\/blood-2004-07-2929","article-title":"Transfusion-related acute lung injury.","volume":"105","author":"Silliman","year":"2005","journal-title":"Blood"},{"key":"2019111715260241900_B30","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1046\/j.1537-2995.1980.20681057154.x","article-title":"Transfusion-associated fatalities: review of Bureau of Biologics reports, 1976-78.","volume":"20","author":"Honig","year":"1980","journal-title":"Transfusion"},{"key":"2019111715260241900_B31","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1046\/j.1537-2995.2000.40101207.x","article-title":"Transfusion errors in New York State.","volume":"40","author":"Linden","year":"2000","journal-title":"Transfusion"},{"key":"2019111715260241900_B32"},{"key":"2019111715260241900_B33","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1046\/j.1537-2995.1991.31591263193.x","article-title":"Improvement in transfusion safety using a new blood-unit and patient identification system as part of safe transfusion practice.","volume":"31","author":"Wenz","year":"1991","journal-title":"Transfusion"},{"key":"2019111715260241900_B34","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1046\/j.1537-2995.2003.00428.x","article-title":"Barcode technology: its role in increasing the safety of blood transfusion.","volume":"43","author":"Turner","year":"2003","journal-title":"Transfusion"},{"key":"2019111715260241900_B35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1046\/j.1423-0410.2003.00313.x","article-title":"An international study of the performance of sample collection from patients.","volume":"85","author":"Dzik","year":"2003","journal-title":"Vox Sang"},{"key":"2019111715260241900_B36","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1046\/j.1537-2995.2002.00126.x","article-title":"Predicting the effect of transfusing only phenotype-matched RBCs to patients with sickle-cell disease: theoretical and practical implications.","volume":"42","author":"Castro","year":"2002","journal-title":"Transfusion"},{"key":"2019111715260241900_B37","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1537-2995.2006.00764.x","article-title":"Additional red-blood-cell alloantibodies after blood transfusions in a non-hematologic alloimmunized patient cohort: is it time to take precautionary measures?","volume":"46","author":"Schonewille","year":"2006","journal-title":"Transfusion"},{"key":"2019111715260241900_B38","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.tmrv.2007.12.002","article-title":"Integrating molecular technologies for red-blood-cell typing and compatibility testing into blood centers and transfusion services.","volume":"22","author":"Hillyer","year":"2008","journal-title":"Transfus Med Rev"},{"key":"2019111715260241900_B39","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0887-7963(00)80115-7","article-title":"Camouflaged blood cells: low-technology bioengineering for transfusion medicine?","volume":"14","author":"Scott","year":"2000","journal-title":"Transfus Med Rev"},{"key":"2019111715260241900_B40","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/j.1537-2995.2007.01281.x","article-title":"The impact of universal leukodepletion of the blood supply on hemovigilance reports of post-transfusion purpura and transfusion-associated graft-versus-host disease.","volume":"47","author":"Williamson","year":"2007","journal-title":"Transfusion"},{"key":"2019111715260241900_B41","first-page":"377","article-title":"Transfusion-associated graft-versus-host disease with transfusion practice in cardiac surgery.","volume":"41","author":"Yasuura","year":"2000","journal-title":"J Cardiovasc Surg"},{"key":"2019111715260241900_B42","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1046\/j.1423-0410.1999.7610059.x","article-title":"Transfusion-associated graft-versus-host disease in an immunocompetent patient following cardiac surgery.","volume":"76","author":"Rososhansky","year":"1999","journal-title":"Vox Sang"},{"key":"2019111715260241900_B43","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1537-2995.1996.36296181918.x","article-title":"Transfusion-associated graft-versus-host disease in the neonate: expanding the spectrum of disease.","volume":"36","author":"Luban","year":"1996","journal-title":"Transfusion"},{"key":"2019111715260241900_B44","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0955-3886(95)00020-X","article-title":"Current trends: evolving concepts in transfusion medicine. Leukodepleted cellular blood components for prevention of transfusion-associated graft-versus-host disease.","volume":"16","author":"Anderson","year":"1995","journal-title":"Transfus Sci"},{"key":"2019111715260241900_B45","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0140-6736(96)06168-5","article-title":"Randomized comparison of leukocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery.","volume":"348","author":"Jensen","year":"1996","journal-title":"Lancet"},{"key":"2019111715260241900_B46","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0305-4179(98)00157-0","article-title":"Pre-storage leukocyte filtration may reduce leukocyte-derived bioactive substance accumulation in patients operated for burn trauma.","volume":"25","author":"Nielsen","year":"1999","journal-title":"Burns"},{"key":"2019111715260241900_B47","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s003840100298","article-title":"Leukocyte-depletion of blood components does not significantly reduce the risk of infectious complications: results of a double-blind, randomized study.","volume":"16","author":"Titlestad","year":"2001","journal-title":"Int J Colorectal Dis"},{"key":"2019111715260241900_B48","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1046\/j.1537-2995.2002.00182.x","article-title":"A prospective, randomized clinical trial of universal WBC reduction.","volume":"42","author":"Dzik","year":"2002","journal-title":"Transfusion"},{"key":"2019111715260241900_B49","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1046\/j.1537-2995.2002.00181.x","article-title":"Effect of WBC reduction of transfused RBCs on postoperative infection rates in cardiac surgery.","volume":"42","author":"Wallis","year":"2002","journal-title":"Transfusion"},{"key":"2019111715260241900_B50","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1136\/bmj.38103.735266.55","article-title":"Effects of transfusion with red cells filtered to remove leukocytes: randomized controlled trial in patients undergoing major surgery.","volume":"328","author":"van Hilten","year":"2004","journal-title":"BMJ"},{"key":"2019111715260241900_B51","first-page":"5S","article-title":"Leukocyte-reduced blood in open-heart surgery patients: effects on outcome.","volume":"42","author":"Bracey","year":"2002","journal-title":"Transfusion"},{"key":"2019111715260241900_B52","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/01.shk.0000228171.32587.a1","article-title":"The effects of leukoreduced blood transfusion on infection risk following injury: a randomized controlled trial.","volume":"26","author":"Nathens","year":"2006","journal-title":"Shock"},{"key":"2019111715260241900_B53","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1423-0410.2006.00889.x","article-title":"White-blood-cell-containing allogeneic blood transfusion and postoperative infection or mortality: an updated meta-analysis.","volume":"92","author":"Vamvakas","year":"2007","journal-title":"Vox Sang"},{"key":"2019111715260241900_B54","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1423-0410.2008.01100.x","article-title":"Transfusion-related immunomodulation: a second hit in an inflammatory cascade?","volume":"95","author":"Bilgin","year":"2008","journal-title":"Vox Sang"},{"key":"2019111715260241900_B55","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.blre.2007.07.003","article-title":"Transfusion-related immunomodulation (TRIM): an update.","volume":"21","author":"Vamvakas","year":"2007","journal-title":"Blood Rev"},{"key":"2019111715260241900_B56","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1056\/NEJMoa070403","article-title":"Duration of red-cell storage and complications after cardiac surgery.","volume":"358","author":"Koch","year":"2008","journal-title":"N Engl J Med"},{"key":"2019111715260241900_B57","first-page":"684","article-title":"Partial characterization of lipids that develop during the routine storage of blood and prime the neutrophil NADPH oxidase.","volume":"124","author":"Silliman","year":"1994","journal-title":"J Lab Clin Med"},{"key":"2019111715260241900_B58","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00024382-200013010-00006","article-title":"Stored red blood cells selectively activate human neutrophils to release IL-8 and secretory PLA2.","volume":"13","author":"Zallen","year":"2000","journal-title":"Shock"},{"key":"2019111715260241900_B59","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1423-0410.2008.01117.x","article-title":"Current issues related to the transfusion of stored red blood cells.","volume":"96","author":"Zimm","year":"2009","journal-title":"Vox Sang"},{"key":"2019111715260241900_B60","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJM199902113400601","article-title":"A multicenter randomized controlled trial of transfusion requirements in critical care.","volume":"340","author":"H\u00e9bert","year":"1999","journal-title":"N Engl J Med"},{"key":"2019111715260241900_B61","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1046\/j.1537-2995.2002.00174.x","article-title":"Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population.","volume":"42","author":"Dodd","year":"2002","journal-title":"Transfusion"},{"key":"2019111715260241900_B62","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0887-7963(03)00019-1","article-title":"Uses and sources of data on long-term survival after blood transfusion.","volume":"17","author":"Vamvakas","year":"2003","journal-title":"Transfus Med Rev"},{"key":"2019111715260241900_B63","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1046\/j.1537-2995.1999.39050479.x","article-title":"Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma.","volume":"39","author":"Pereira","year":"1999","journal-title":"Transfusion"},{"key":"2019111715260241900_B64","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1046\/j.1537-2995.2000.40101182.x","article-title":"A model of the health and economic impact of post-transfusion hepatitis C: application to cost-effectiveness analysis of further expansion of HCV screening protocols.","volume":"40","author":"Pereira","year":"2000","journal-title":"Transfusion"},{"key":"2019111715260241900_B65","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1046\/j.1537-2995.2003.00280.x","article-title":"Health and economic impact of post-transfusion hepatitis B and cost effectiveness analysis of expanded HBV testing protocols of blood donors: a study focused on the European Union.","volume":"43","author":"Pereira","year":"2003","journal-title":"Transfusion"},{"key":"2019111715260241900_B66","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/j.0041-1132.2004.04130.x","article-title":"West Nile virus blood transfusion-related infection despite nucleic acid testing.","volume":"44","author":"Macedo de Oliveira","year":"2004","journal-title":"Transfusion"},{"key":"2019111715260241900_B67","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMc0708673","article-title":"Dengue hemorrhagic fever transmitted by blood transfusion.","volume":"359","author":"Tambyah","year":"2008","journal-title":"N Engl J Med"},{"key":"2019111715260241900_B68","unstructured":"National CJD Surveillance Unit.\n          Accessed June 2, 2008\n          \n            www.cjd.ed.ac.uk\/figures.htm"},{"key":"2019111715260241900_B69","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2334-3-4","article-title":"Updated projections of future vCJD deaths in the UK.","volume":"3","author":"Ghani","year":"2003","journal-title":"BMC Infect Dis"},{"key":"2019111715260241900_B70","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/path.1580","article-title":"Prevalence of lymphorecticular prion protein accumulation in UK tissue samples.","volume":"203","author":"Hilton","year":"2004","journal-title":"J Pathol"},{"key":"2019111715260241900_B71","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1126\/science.1129051","article-title":"Pre-symptomatic detection of prions in blood.","volume":"313","author":"Saa","year":"2006","journal-title":"Science"},{"key":"2019111715260241900_B72","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1046\/j.1537-2995.2001.41070857.x","article-title":"Single-donor platelets reduce the risk of septic platelet transfusion reactions.","volume":"41","author":"Ness","year":"2001","journal-title":"Transfusion"},{"key":"2019111715260241900_B73","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1046\/j.1537-2995.2001.41070862.x","article-title":"Determinants of transfusion-associated bacterial contamination: results of the French BACTHEM case-control study.","volume":"41","author":"for the BACTHEM Group, French Hemovigilance Network","year":"2001","journal-title":"Transfusion"},{"key":"2019111715260241900_B74","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1046\/j.1537-2995.2001.41121493.x","article-title":"Transfusion-transmitted bacterial infection in the United States, 1998 through 2000.","volume":"41","author":"Kuehnert","year":"2001","journal-title":"Transfusion"},{"key":"2019111715260241900_B75","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1017\/CBO9780511545245.011","article-title":"Bacterial contamination in blood and blood components.","volume-title":"Transfusion Microbiology","author":"McDonald","year":"2008"},{"key":"2019111715260241900_B76","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1046\/j.1537-2995.2000.40111308.x","article-title":"Growth of bacteria in inoculated platelets: implications for bacterial detection and the extension of platelet storage.","volume":"40","author":"Brecher","year":"2000","journal-title":"Transfusion"},{"key":"2019111715260241900_B77","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1046\/j.1537-2995.1995.35495216077.x","article-title":"Comparison of bacterial growth in single and pooled platelet concentrates after deliberate inoculation and storage.","volume":"35","author":"Wagner","year":"1995","journal-title":"Transfusion"},{"key":"2019111715260241900_B78","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1423-0410.2008.01051.x","article-title":"Screening platelet concentrates for bacterial contamination: low numbers of bacteria and slow growth in contaminated units mandate an alternate approach to product safety.","volume":"95","author":"Murphy","year":"2008","journal-title":"Vox Sang"},{"key":"2019111715260241900_B79","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1537-2995.2007.01326.x","article-title":"The residual risk of sepsis: modeling the effect of concentration on bacterial detection in two-bottle culture systems and an estimation of false-negative culture rates.","volume":"47","author":"Benjamin","year":"2007","journal-title":"Transfusion"},{"key":"2019111715260241900_B80","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/j.1537-2995.2007.01248.x","article-title":"Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: the American Red Cross experience (2004-2006).","volume":"47","author":"Eder","year":"2007","journal-title":"Transfusion"},{"key":"2019111715260241900_B81","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1046\/j.1537-2995.2001.41050691.x","article-title":"Universal WBC reduction: the case for and against.","volume":"41","author":"Vamvakas","year":"2001","journal-title":"Transfusion"},{"key":"2019111715260241900_B82","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1111\/j.1537-2995.2006.01010.x","article-title":"Managing threats rather than risks in blood transfusion: robust design for a complex system.","volume":"46","author":"Murphy","year":"2006","journal-title":"Transfusion"},{"key":"2019111715260241900_B83","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1046\/j.1537-2995.1987.27587320525.x","article-title":"Estimating the risks of transfusion-associated acquired immune deficiency syndrome and human immunodeficiency virus infection.","volume":"27","author":"Peterman","year":"1987","journal-title":"Transfusion"},{"key":"2019111715260241900_B84","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1053\/jhep.2001.21905","article-title":"Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung and Blood Institute Collaborative Study.","volume":"33","author":"Seef","year":"2001","journal-title":"Hepatology"},{"key":"2019111715260241900_B85","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.tmrv.2004.11.005","article-title":"Protecting the blood supply from emerging pathogens: the role of pathogen inactivation.","volume":"19","author":"Allain","year":"2005","journal-title":"Transfus Med Rev"},{"key":"2019111715260241900_B86","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1111\/j.1537-2995.2007.01539.x","article-title":"Pathogen inactivation: a new paradigm for blood safety.","volume":"47","author":"McCullough","year":"2007","journal-title":"Transfusion"},{"key":"2019111715260241900_B87","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1537-2995.2007.01512.x","article-title":"Pathogen inactivation: making decisions about new technologies. Report of a consensus conference.","volume":"47","author":"Klein","year":"2007","journal-title":"Transfusion"},{"key":"2019111715260241900_B88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tmrv.2008.09.001","article-title":"Cost-effectiveness analysis: what it really means for transfusion medicine decision making.","volume":"23","author":"Custer","year":"2009","journal-title":"Transfus Med Rev"},{"key":"2019111715260241900_B89","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1136\/bmj.328.7445.934","article-title":"Effect of flow chart on use of blood transfusions in primary total-hip and knee replacement: prospective before-and-after study.","volume":"328","author":"Muller","year":"2004","journal-title":"Br Med J"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/113\/15\/3406\/1483850\/zh801509003406.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/113\/15\/3406\/1483850\/zh801509003406.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T15:26:36Z","timestamp":1574004396000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/113\/15\/3406\/24952\/Transfusionrelated-mortality-the-ongoing-risks-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,9]]},"references-count":89,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2009,4,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2008-10-167643","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,9]]}}}